Seattle Cancer Care Alliance Selected as an Authorized Treatment Center for BreyanziTM/Liso-Cel CAR T-Cell Treatment

Cancer center among the first in the nation to offer the newly approved cell therapy for adults with certain types of large B-cell lymphoma.

B-cell lymphoma A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are many different types of B-cell non-Hodgkin lymphomas. These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Prognosis and treatment depend on the type and stage of the cancer.

SEATTLE (February 18, 2021) – Seattle Cancer Care Alliance (SCCA), the only NCCN-designated cancer center in Washington State, has been selected as an authorized treatment center for the new chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel, also known as liso-cel and by the brand name BreyanziTM. Liso-cel was approved by the U.S. Food and Drug Administration (FDA) on February 5, 2021. 

The CD19-directed CAR T-cell therapy is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B. Liso-cel is not indicated for the treatment of patients with primary central nervous system lymphoma. According to the pivotal multi-center phase 1 TRANSCEND NHL 001 trial, treatment with liso-cel resulted in a response rate of 73% and a complete response (CR) rate of 53%; these data supported the priority review granted by the FDA in mid-2020.  
 
“The recent FDA approval of lisocabtagene maraleucel marks a significant step forward in CAR T-cell therapies for the treatment of large B-cell lymphoma, offering a potential life-saving option for those whose cancer hasn’t responded to other treatments or has returned,” said David Maloney, MD, PhD, medical director for cellular immunotherapy at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance. “We are very excited to be one of the authorized centers to offer an advancing therapy that has the potential to benefit more than 80,000 patients nationwide.”  

Large B-cell lymphoma is the most common type of non-Hodgkin lymphoma and is a rapidly growing, aggressive disease, accounting for one of every three non-Hodgkin lymphoma cases diagnosed, according to the American Cancer Society. When large B-cell lymphoma has returned following treatment or not responded to treatment, it is considered to have reached relapsed or refractory state.  According to previous studies, as many as 73% of patients will not respond to second-line treatment, or they will relapse. In patients who relapse or do not respond to initial therapies, conventional treatment options that provide sustained responses are limited, with an average life expectancy of about six months.  

The liso-cel treatment is prepared from a patient’s own cells. Blood is withdrawn, T cells are separated and then undergo genetic “reprogramming” to become CAR T cells, which are multiplied for the patient’s appropriate dose and administered via an infusion at a treatment center like SCCA’s Bezos Family Immunotherapy Clinic. Liso-cel has been infused and monitored in outpatient settings in three trials. According to a study presented last year involving three on-going trials (TRANSCEND NHL 001, Outreach and PILOT), the need for hospitalization was low following treatment with liso-cel. After the first month of treatment, approximately 40% of patients did not require hospitalization. 

“SCCA’s mission is to ensure that our patients have access to the latest treatment advances and leading-edge therapies,” said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance. “We are pleased to add another treatment offering to patients suffering from relapsed or refractory large B-cell lymphoma and advance our mission of pursuing better, longer, richer lives for our patients.”

With this latest FDA approval, SCCA is one of the first cancer treatment centers in the United States to offer all four FDA-approved CAR T-cell therapies. The organization provides a broad range of treatment resources and advanced clinical trials; there are currently 20 cellular therapy clinical trials open for enrollment. The organization is home to several of the world’s leading immunotherapy experts whose research has contributed to the foundation of many immunotherapies currently used to treat cancer. SCCA’s Bezos Family Immunotherapy Clinic, which opened in 2016, is a state-of-the-art center dedicated to offering the newest clinical trials and therapies in cellular immunotherapy.

 

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children’s and UW Medicine — one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattle’s South Lake Union neighborhood, Seattle Cancer Care Alliance has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology/medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center - Northwest Seattle and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.

 

Contacts 

Karina San Juan, ksanjuangu@seattlecca.org or (206) 606-1926 

Heather Platisha, hplatisha@seattlecca.org or (206) 606-7239

Antigen A foreign substance, such as bacteria, that causes the body’s immune system to respond by making antibodies. Antibodies defend the body against antigens. B-cell lymphoma A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. A type of cancer that forms in B cells (a type of immune system cell). B-cell lymphomas may be either indolent (slow-growing) or aggressive (fast-growing). Most B-cell lymphomas are non-Hodgkin lymphomas. There are many different types of B-cell non-Hodgkin lymphomas. These include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Prognosis and treatment depend on the type and stage of the cancer. Chimeric antigen receptor T-cell therapy A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then, in the laboratory, the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells. This special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called CAR T-cell therapy. Clinical trial A type of research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis or treatment of a disease. Follicular lymphoma A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually indolent (slow-growing). The tumor cells grow as groups to form nodules. A type of B-cell non-Hodgkin lymphoma (cancer of the immune system) that is usually indolent (slow-growing). The tumor cells grow as groups to form nodules. There are several subtypes of follicular lymphoma. Grade In cancer, a grade is a description of a tumor based on how abnormal the cancer cells and tissue look under a microscope and how quickly the cancer cells are likely to grow and spread. In cancer, a grade is a description of a tumor based on how abnormal the cancer cells and tissue look under a microscope and how quickly the cancer cells are likely to grow and spread. Low-grade cancer cells look more like normal cells and tend to grow and spread more slowly than high-grade cancer cells. Grading systems are different for each type of cancer. They are used to help plan treatment and determine prognosis. Also called histologic grade and tumor grade. Immunotherapy A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. A therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. Some immunotherapies only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG) and some monoclonal antibodies. Immunotherapy A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. A therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection and other diseases. Some immunotherapies only target certain cells of the immune system. Others affect the immune system in a general way. Types of immunotherapy include cytokines, vaccines, bacillus Calmette-Guerin (BCG) and some monoclonal antibodies. Indolent Slow-growing. Infusion An injection of medications or fluids into a vein over a period of time. Lymphoma Cancer that begins in the cells of the immune system. There are two basic categories of lymphomas: Hodgkin lymphoma and non-Hodgkin lymphomas. Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer. Non-Hodgkin lymphoma Any of a large group of cancers of the lymphocytes (white blood cells). Non-Hodgkin lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever and weight loss. Any of a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin lymphomas can occur at any age and are often marked by lymph nodes that are larger than normal, fever and weight loss. There are many different types of non-Hodgkin lymphoma. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either B cells or T cells. B-cell non-Hodgkin lymphomas include Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and mantle cell lymphoma. T-cell non-Hodgkin lymphomas include mycosis fungoides, anaplastic large cell lymphoma and precursor T-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas. Prognosis and treatment depend on the stage and type of disease. Also called NHL. Refractory In medicine, refractory disease is a disease or condition that does not respond to treatment. Relapse The recurrence (return) of disease after an apparent recovery. Relapse The recurrence (return) of disease after an apparent recovery. Systemic therapy Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body. T cell A type of white blood cell. T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. A type of white blood cell. T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. Also called T lymphocyte and thymocyte. T lymphocyte A type of white blood cell. T lymphocytes are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. A type of white blood cell. T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer. Also called T cells and thymocyte.